<DOC>
	<DOCNO>NCT00001384</DOCNO>
	<brief_summary>This pilot feasibility trial AC ( Adriamycin , cyclophosphamide ) chemotherapy G-CSF ( filgrastim ) follow infusional Taxol ( paclitaxel ) adjuvant treatment patient high risk stage II stage III breast cancer . Cycles 14 day duration . After 3 fourteen day cycle AC filgrastim , patient treat 3 fourteen day cycle 96 hour infusional paclitaxel . The goal study assess toxicity feasibility administer dose-intensive AC chemotherapy follow infusional paclitaxel 14 day cycle .</brief_summary>
	<brief_title>A Pilot Trial AC ( Adriamycin , Cyclophosphamide ) Chemotherapy With G-CSF ( Granulocyte Colony-Stimulating Factor ) Followed Infusional Taxol ( Paclitaxel ) Adjuvant Treatment High Risk Stage II Stage III Breast Cancer Patients</brief_title>
	<detailed_description>This pilot feasibility trial AC ( Adriamycin® ( Registered Trademark ) , cyclophosphamide ) chemotherapy G-CSF ( filgrastim ) follow infusional Taxol® ( Registered Trademark ) ( paclitaxel ) adjuvant treatment patient high risk stage II stage III breast cancer . Cycles 14 day duration . After 3 fourteen day cycle AC filgrastim , patient treat 3 fourteen day cycle 96 hour infusional paclitaxel . The goal study assess toxicity feasibility administer dose-intensive AC chemotherapy follow infusional paclitaxel 14 day cycle .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>Recently diagnose patient histologically proven Stage II breast cancer 4 positive lymph node patient stage III breast cancer eligible study . Patients eligible study either receive adjuvant radiation therapy . Patients stage III disease eligible receive regimen neoadjuvant chemotherapy adjuvant therapy surgery perform prior patient referral . Patients must previously untreated chemotherapy . There must history previous malignancy except cured nonmelanoma skin cancer ( basal squamous cell carcinoma ) , cervical cancer situ , past malignancy inactive 5 year . Patients prior history lower stage contralateral breast cancer , treat surgery , and/or radiation , chemotherapy , eligible study . Performance status ( Karnofsky scale ) must great 70 ; ECOG 0 2 . Absolute granulocyte count great 1500 per microliter platelet count great 100,000 per mm ( 3 ) . Liver function test ( SGOT , total bilirubin ) less 2X upper limit normal . Serum creatinine le 1.7 creatinine clearance great 45 ml per min . The patient must able give informed consent , return NCI treatment adequate followup period protocol require . Patients must great equal 18 year age . Patients and/or partner must willing practice nonhormonal method contraception therapy 6 month follow therapy . Patients poor medical psychiatric risk nonmalignant systemic disease would preclude subjected treatment protocol exclude . Patients must normal ejection fraction MUGA scan angina . Patients currently require therapy cardiac arrhythmia , congestive heart failure , coronary artery disease . No patient history symptomatic CNS disease . No patient allergy study medication . No pregnant lactate woman . Patients bleed disorder ineligible study entry patient require chronic anticoagulation .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2000</verification_date>
	<keyword>14-Day Cycle</keyword>
	<keyword>Dose Intensity</keyword>
	<keyword>Filgrastim</keyword>
	<keyword>Lymph Node Positive</keyword>
	<keyword>Non-Cross Resistant</keyword>
</DOC>